AI assistant
Laurus Labs Limited — Call Transcript 2020
Oct 26, 2020
62639_rns_2020-10-26_156fd395-e076-44fe-bee1-9951d0c7038e.pdf
Call Transcript
Open in viewerOpens in your device viewer
==> picture [114 x 37] intentionally omitted <==
LAURUS LABS LIMITED
LAURUS LABS LTD. Q2 & H1 FY21 RESULTS CONFERENCE CALL ON FRIDAY, OCTOBER 30, 2020 AT 11:00 AM IST
Laurus Labs Ltd. (Laurus), a leading research and development driven pharmaceutical company in India, will organize a conference call for Investors and Analysts, on Friday, October 30, 2020 at 11:00 am IST.
The conference call will be initiated with a brief management discussion on the Q2 & H1 FY21 results, followed by an interactive Question & Answer session. The call will be hosted by Kotak Institutional Equities.
Details of the conference call are as follows:
For Diamond pass please Copy this URL in your browser:
https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=0632468&linkSecurityString=1ca119acc
| Timing | 11:00 am IST on Friday, October 30, 2020 |
|---|---|
| Conference dial-in | |
| Primarynumber | +91 22 6280 1214 |
| SecondaryNumber | +91 7045671221_Available all over India_ |
| Singapore | +6531575746 |
| HongKong | +85230186877 |
| USA | +13233868721 |
| UK | +442034785524 |
- ENDS –
==> picture [171 x 67] intentionally omitted <==
OCTOBER 26, 2020
PAGE 2
==> picture [113 x 36] intentionally omitted <==
About Laurus Labs Ltd.
Laurus Labs is a leading research driven Pharmaceutical Manufacturing Company in India. We have grown to become one of the leading manufacturers of API for Anti-Retroviral (ARV), Oncology, Cardiovascular, Anti-Diabetics, Anti-Asthma and Gastroenterology. We are thriving on growth opportunities in formulation manufacturing to service all leading markets of North America, Europe and Low Middle Income Countries (LMIC). We are driving growth opportunities in Contract Development and Manufacturing through our Synthesis business. Most of our manufacturing facilities are approved by major regulatory authorities USFDA, WHO-Geneva, UKMHRA etc. Our approach remains to identify and invest ahead of time with strategic investments in State-of-the-Art R&D and Manufacturing Infrastructure enabling us to become a quality supplier of high volume products. Corporate Identification No: L24239AP2005PLC047518
For further information, please contact
Monish Shah
Laurus Labs Limited Tel: +91 40 6659 4366 Email: [email protected]
==> picture [171 x 66] intentionally omitted <==
OCTOBER 26, 2020